07:00 , Sep 27, 2004 |  BioCentury  |  Finance

Ebb & Flow

BioMarin's first announcement related to Orapred, the flagship of its new pediatrics focus, wasn't a great one, as the company expects no revenue contribution from the pediatric asthma drug in the second half. Moreover, there's...
07:00 , Sep 20, 2004 |  BC Extra  |  Financial News

Novagali completes EUR 14.2M series B

Drug delivery company Novagali (Evry, France) raised EUR 9.2 million ($11.2 million) in a second closing of series B round, bringing the total raised in the round to EUR 14.2 million ($17.3 million). New investors...